Effect of dual drug therapy with coamoxiclav-based on Helicobacter pylori eradicatio
Phase 3
Recruiting
- Conditions
- Helicobacter pylori infection.Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhereB96.81
- Registration Number
- IRCT20201213049694N1
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 188
Inclusion Criteria
Helicobacter pylori serology test is positive
Severe disorders affecting the gastrointestinal tract
Exclusion Criteria
Gastrointestinal malignancy
Pregnant and lactating
History of radiotherapy
Allergy to any of the antibiotics used in the study
Active gastrointestinal bleeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Helicobacter pylori eradication. Timepoint: After 2weeks of completion of treatment. Method of measurement: Urea breath test.
- Secondary Outcome Measures
Name Time Method Drug Side effects. Timepoint: During and after the course of treatment. Method of measurement: Ask the patient.